SG/PUT/NOVO-NORDISK B/1000/0.1/20.06.25 Stock

DE000SW7HU27

Market Closed - Bid/Ask 14:04:46 2024-07-03 EDT
1.97 ^EUR	+10.06%

Current month	+0.56%
1 month	-20.80%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/PUT/NOVO-NORDISK B/1000/0.1/20.06.25

Latest news about NOVO NORDISK A/S

Sector Update: Health Care Stocks Fall in Afternoon Trading	12:52pm	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	12:08pm	MT
Top Midday Stories: Southwest Board Approves Shareholder Rights Plan; National Amusements Agrees to Preliminary Deal to Sell Paramount to Skydance; Ozempic, Wegovy Linked to Blinding Eye Condition, Study Says	11:59am	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	11:51am	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-03	1.97	+10.06%
24-07-02	1.79	+7.19%
24-07-01	1.67	-6.18%
24-06-28	1.78	+1.71%
24-06-27	1.75	+0.57%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 02:04 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SW7HU2
ISIN	DE000SW7HU27
Date issued	2024-03-11
Strike	1,000 kr
Maturity	2025-06-20 (352 Days)
Parity	10 : 1
Emission price	2.63 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.08 €
Lowest since issue	1.6 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	6.53x
Moneyness	1.034
Difference Strike	32.5 kr
Difference Strike %	+3.25%
Spread	0.05 €
Spread %	2.49%
Intrinsic value	0.4353
Present value	1.550

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company